Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.64
DRRX's Cash to Debt is ranked higher than
50% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. DRRX: 1.64 )
Ranked among companies with meaningful Cash to Debt only.
DRRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.63  Med: 21.93 Max: No Debt
Current: 1.64
Equity to Asset 0.36
DRRX's Equity to Asset is ranked lower than
83% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DRRX: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
DRRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.46 Max: 0.96
Current: 0.36
0.07
0.96
F-Score: 5
Z-Score: -9.00
M-Score: -3.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -113.52
DRRX's Operating margin (%) is ranked lower than
91% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. DRRX: -113.52 )
Ranked among companies with meaningful Operating margin (%) only.
DRRX' s Operating margin (%) Range Over the Past 10 Years
Min: -164.81  Med: -94.12 Max: 30.25
Current: -113.52
-164.81
30.25
Net-margin (%) -124.87
DRRX's Net-margin (%) is ranked lower than
91% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. DRRX: -124.87 )
Ranked among companies with meaningful Net-margin (%) only.
DRRX' s Net-margin (%) Range Over the Past 10 Years
Min: -162.01  Med: -96.65 Max: 30.53
Current: -124.87
-162.01
30.53
ROE (%) -116.53
DRRX's ROE (%) is ranked lower than
95% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. DRRX: -116.53 )
Ranked among companies with meaningful ROE (%) only.
DRRX' s ROE (%) Range Over the Past 10 Years
Min: -208.92  Med: -86.37 Max: 81.39
Current: -116.53
-208.92
81.39
ROA (%) -45.54
DRRX's ROA (%) is ranked lower than
90% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. DRRX: -45.54 )
Ranked among companies with meaningful ROA (%) only.
DRRX' s ROA (%) Range Over the Past 10 Years
Min: -55.27  Med: -34.29 Max: 34.06
Current: -45.54
-55.27
34.06
ROC (Joel Greenblatt) (%) -790.75
DRRX's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. DRRX: -790.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DRRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -977.57  Med: -641.37 Max: 500.45
Current: -790.75
-977.57
500.45
Revenue Growth (3Y)(%) -23.50
DRRX's Revenue Growth (3Y)(%) is ranked lower than
91% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. DRRX: -23.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DRRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 2.80 Max: 52.3
Current: -23.5
0
52.3
EBITDA Growth (3Y)(%) -3.50
DRRX's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. DRRX: -3.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DRRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.8  Med: -6.35 Max: 39.2
Current: -3.5
-35.8
39.2
EPS Growth (3Y)(%) -2.70
DRRX's EPS Growth (3Y)(%) is ranked lower than
63% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. DRRX: -2.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DRRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: -9.45 Max: 27.6
Current: -2.7
-28.3
27.6
» DRRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

DRRX Guru Trades in Q4 2014

Robert Bruce 1,215,973 sh (unchged)
First Eagle Investment 10,707,142 sh (unchged)
Jim Simons 17,800 sh (-34.56%)
» More
Q1 2015

DRRX Guru Trades in Q1 2015

Jim Simons 58,700 sh (+229.78%)
First Eagle Investment 13,196,397 sh (+23.25%)
Robert Bruce 1,215,973 sh (unchged)
» More
Q2 2015

DRRX Guru Trades in Q2 2015

Jim Simons 227,100 sh (+286.88%)
First Eagle Investment 13,196,397 sh (unchged)
Robert Bruce 863,609 sh (-28.98%)
» More
Q3 2015

DRRX Guru Trades in Q3 2015

First Eagle Investment 14,081,446 sh (+6.71%)
Jim Simons 206,800 sh (-8.94%)
Robert Bruce 763,609 sh (-11.58%)
» More
» Details

Insider Trades

Latest Guru Trades with DRRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Durect Corp

Jean-Marie Eveillard Ups Stake in Pharma Company Durect
Former portfolio manager at First Eagle Funds, Jean-Marie Eveillard (Trades, Portfolio), increased his stake in Durect Corp (NASDAQ:DRRX) on March 9 by more than 22%, according to GuruFocus’ Real Time Picks. Read more...

Ratios

vs
industry
vs
history
Forward P/E 5.73
DRRX's Forward P/E is ranked higher than
95% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.75 vs. DRRX: 5.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 7.23
DRRX's P/B is ranked lower than
94% of the 935 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. DRRX: 7.23 )
Ranked among companies with meaningful P/B only.
DRRX' s P/B Range Over the Past 10 Years
Min: 1.68  Med: 8.24 Max: 38.38
Current: 7.23
1.68
38.38
P/S 6.50
DRRX's P/S is ranked lower than
90% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.60 vs. DRRX: 6.50 )
Ranked among companies with meaningful P/S only.
DRRX' s P/S Range Over the Past 10 Years
Min: 0.92  Med: 8.94 Max: 20.19
Current: 6.5
0.92
20.19
Current Ratio 5.91
DRRX's Current Ratio is ranked higher than
83% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. DRRX: 5.91 )
Ranked among companies with meaningful Current Ratio only.
DRRX' s Current Ratio Range Over the Past 10 Years
Min: 1.48  Med: 5.82 Max: 29.59
Current: 5.91
1.48
29.59
Quick Ratio 5.32
DRRX's Quick Ratio is ranked higher than
82% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. DRRX: 5.32 )
Ranked among companies with meaningful Quick Ratio only.
DRRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.41  Med: 5.36 Max: 28.73
Current: 5.32
1.41
28.73
Days Inventory 340.61
DRRX's Days Inventory is ranked lower than
94% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. DRRX: 340.61 )
Ranked among companies with meaningful Days Inventory only.
DRRX' s Days Inventory Range Over the Past 10 Years
Min: 215.56  Med: 238.15 Max: 294.87
Current: 340.61
215.56
294.87
Days Sales Outstanding 45.44
DRRX's Days Sales Outstanding is ranked higher than
76% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. DRRX: 45.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.9  Med: 41.43 Max: 57.34
Current: 45.44
14.9
57.34
Days Payable 70.92
DRRX's Days Payable is ranked lower than
52% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. DRRX: 70.92 )
Ranked among companies with meaningful Days Payable only.
DRRX' s Days Payable Range Over the Past 10 Years
Min: 55.54  Med: 97.88 Max: 237.93
Current: 70.92
55.54
237.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 101.00
DRRX's Price/Net Cash is ranked lower than
95% of the 287 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.70 vs. DRRX: 101.00 )
Ranked among companies with meaningful Price/Net Cash only.
DRRX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.33  Med: 17.30 Max: 525
Current: 101
2.33
525
Price/Net Current Asset Value 14.43
DRRX's Price/Net Current Asset Value is ranked lower than
74% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DRRX: 14.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DRRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.03  Med: 11.29 Max: 172.5
Current: 14.43
2.03
172.5
Price/Tangible Book 11.22
DRRX's Price/Tangible Book is ranked lower than
83% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.74 vs. DRRX: 11.22 )
Ranked among companies with meaningful Price/Tangible Book only.
DRRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.37  Med: 7.86 Max: 203
Current: 11.22
1.37
203
Price/Median PS Value 0.71
DRRX's Price/Median PS Value is ranked higher than
84% of the 924 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. DRRX: 0.71 )
Ranked among companies with meaningful Price/Median PS Value only.
DRRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.24 Max: 10.49
Current: 0.71
0.12
10.49
Earnings Yield (Greenblatt) (%) -18.74
DRRX's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. DRRX: -18.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DRRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.74  Med: 29.55 Max: 49
Current: -18.74
-18.74
49

More Statistics

Revenue(Mil) $18
EPS $ -0.19
Beta0.96
Short Percentage of Float3.15%
52-Week Range $0.90 - 3.42
Shares Outstanding(Mil)120.53

Analyst Estimate

Dec15 Dec16
Revenue(Mil)
EPS($) -0.25 -0.23
EPS without NRI($) -0.25 -0.23

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DC8.Germany,
Durect Corp was incorporated in Delaware in February 1998. The Company is a specialty pharmaceutical company engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms. The Company's product pipeline currently consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).The Company has other programs underway in fields outside of pain management, including several efforts underway which seek to improve the administration of biotechnology agents such as proteins and peptides. The Company's development efforts are focused on the application of its pharmaceutical systems technologies to potential products in a variety of chronic and episodic disease areas including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases. Its product candidate include Remoxy (Oral controlled release oxycodone); POSIDUR (Controlled release injection of bupivacaine); ELADUR (Transdermal bupivacaine); TRANSDUR-Sufentanil (Transdermal sufentanil); ORADUR-based opioid (hydrocodone); ORADUR-based opioid (hydromorphone); ORADUR-ADHD; ORADUR-based opioid (oxymorphone); and Relday (risperidone). Its pharmaceutical systems enable optimized therapy for a given disease or patient population by controlling the rate and duration of drug administration. The Company has several technology platforms: Bioerodible Injectable Depot Systems, The TRANSDUR Transdermal Delivery System, The ORADUR Sustained Release Gel Cap Technology, and The DURIN Biodegradable Implant Technology. POSIDUR, SABER, CLOUD, TRANSDUR, ORADUR, ELADUR, DURIN, CHRONOGESIC, MICRODUR, ALZET and LACTEL are the trademarks of the Company. The manufacturing and marketing of its pharmaceutical systems and its research and development activities are subject to extensive regulation for safety, efficacy and quality by numerous government authorities in the United States and abroad.
» More Articles for DRRX

Headlines

Articles On GuruFocus.com
Jean-Marie Eveillard and Arnold Van Den Berg Raise Stakes in Small-Cap Stocks Mar 24 2015 
Jean-Marie Eveillard Ups Stake in Pharma Company Durect Mar 23 2015 
Durect Corp. Reports Operating Results (10-Q) Nov 04 2010 
Durect Corp. Reports Operating Results (10-Q) Aug 05 2010 
Opportunistic Coat-tailing Jan 05 2010 
Durect Corp. Reports Operating Results (10-Q) Nov 02 2009 
Durect Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
DURECT Corp.'s CEO James E. Brown Interviewed by The Life Sciences Report Feb 02 2016
DURECT CORP Files SEC form 8-K, Change in Directors or Principal Officers Feb 01 2016
DURECT to Present at the BIO CEO & Investor Conference Jan 28 2016
Could This Company Be The Best Way To Capitalize On Opioid Crisis? Jan 25 2016
What Investors Need To Know About The Billion Dollar Opioid Opportunity Jan 25 2016
DURECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 11 2016
DURECT Announces Initiation of DUR-928 Dosing in Patients Jan 11 2016
Edited Transcript of DRRX earnings conference call or presentation 2-Nov-15 9:30pm GMT Jan 07 2016
DURECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2016
DURECT Announces Positive Phase 1 Data for DUR-928 Jan 06 2016
DURECT Corp. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
Timing is Crucial, Upside Analysis - Analyst Notes on DURECT, HC2 Holdings, Mirna Therapeutics and... Dec 18 2015
DURECT CORP Financials Dec 08 2015
Is DURECT Corporation (NASDAQ:DRRX) A Good Stock To Buy? Dec 06 2015
DURECT to Present at the Oppenheimer Healthcare Conference Nov 30 2015
Be On Top Of The Latest Developments - Research on Checkpoint Systems, DURECT, Tokai Pharmaceuticals... Nov 24 2015
Trading Ahead of Upcoming Developments- Research on Checkpoint Systems, W&T Offshore, DURECT and... Nov 16 2015
DURECT to Present at the Stifel Nicolaus Healthcare Conference Nov 05 2015
DURECT CORP Files SEC form 10-Q, Quarterly Report Nov 03 2015
DRRX: Durect Exited Third Quarter 2015 with a Strong Balance Sheet Nov 03 2015
Durect reports 3Q loss Nov 02 2015
Durect reports 3Q loss Nov 02 2015
DURECT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 02 2015
DURECT Corporation Announces Third Quarter 2015 Financial Results and Update of Programs Nov 02 2015
DURECT Corporation Invites You to Join its Third Quarter 2015 Earnings Conference Call Oct 26 2015
DURECT to Participate in Upcoming Healthcare Conferences Aug 27 2015
Durect reports 2Q loss Aug 03 2015
DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs Aug 03 2015
DURECT Corporation Invites You to Join its Second Quarter 2015 Earnings Conference Call Jul 24 2015
DURECT to Present at the Cantor Fitzgerald Healthcare Conference Jun 29 2015
DURECT Announces Plans for a New POSIDUR™ (SABER®-Bupivacaine) Clinical Trial Jun 23 2015
DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study May 18 2015
Durect reports 1Q loss Apr 30 2015
DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs Apr 30 2015
DURECT Corporation Invites You to Join its First Quarter 2015 Earnings Conference Call Apr 22 2015
DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study Mar 30 2015
DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury... Mar 09 2015
DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs Mar 02 2015
Durect reports 4Q loss Mar 02 2015
DURECT Corporation Invites You to Join its Fourth Quarter 2014 Earnings Conference Call Mar 02 2015
Durect posts 3Q loss Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK